What do systematic reviews say?

Subcutaneous insulin aspart vs intravenous regular insulin

The review found no eligible studies for this question.

• Subcutaneous rapid‐acting insulin analogues for diabetic ketoacidosis 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Subcutaneous insulin aspart vs intravenous regular insulin

The review found no eligible studies for this question.

• Subcutaneous rapid‐acting insulin analogues for diabetic ketoacidosis 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Subcutaneous insulin aspart vs intravenous regular insulin

• Subcutaneous rapid‐acting insulin analogues for diabetic ketoacidosis 2016 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 30 participants
  Very low

Subcutaneous insulin aspart vs intravenous regular insulin

The review found no eligible studies for this question.

• Subcutaneous rapid‐acting insulin analogues for diabetic ketoacidosis 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Subcutaneous insulin aspart vs intravenous regular insulin

• Subcutaneous rapid‐acting insulin analogues for diabetic ketoacidosis 2016 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 30 participants
  Low

Subcutaneous insulin aspart vs intravenous regular insulin

• Subcutaneous rapid‐acting insulin analogues for diabetic ketoacidosis 2016 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 45 participants
  Low

Subcutaneous insulin aspart vs intravenous regular insulin

Subcutaneous insulin aspart showed no clear difference in hypoglycaemic episodes (N) Mean hospital stay: 3‐5 days compared with intravenous regular insulin (low certainty).

• Subcutaneous rapid‐acting insulin analogues for diabetic ketoacidosis 2016 · Cochrane Headline outcomes only
  RR 1 [0.07, 14.55]
  1 study · 30 participants
  Low